Russian Mrna Vaccine Cancer: Enteromix, has achieved 100% efficacy and safety in early clinical trials targeting colorectal cancer.

In a breakthrough that reads like a beacon of hope, Russia has announced that its novel cancer vaccine, Enteromix, has demonstrated 100% efficacy and safety in initial human trials.

The news highlights the vaccine's remarkable performance: patients experienced tumour shrinkage and no serious side effects.

Developed using the same mRNA technology as the COVID-19 vaccines, Enteromix is designed to train the immune system to recognize and eliminate cancer cells, a safer, more intelligent alternative to traditional treatments like chemotherapy.

This pioneering therapy is personalized for each colorectal cancer patient, offering a custom immunotherapy tailored to an individual's tumour profile.

The trials involved 48 volunteers and were conducted by Russia's National Medical Research Radiological Centre in collaboration with the Engelhardt Institute of Molecular Biology.

The announcement, made at the 2025 St. Petersburg International Economic Forum, frames this Russian cancer vaccine as a potential game-changer in oncology, one step away from regulatory approval by Russia's Ministry of Health.

Source:Ndtv